Solana Company is a digital asset treasury (DAT) company whose primary objective is to acquire and hold SOL, the native token of the Solana blockchain, on behalf of public market investors. The company's core goal is to maximize SOL per share over time, giving equity investors exposure to SOL without holding the token directly. Solana Company raises capital through equity issuance — including ATM programs, preferred securities, and convertible debt — and deploys proceeds into SOL when the company believes the acquisition is accretive to NAV per share. The company stakes a substantial portion of its SOL holdings to earn yield, with a gross staking yield of 7.3% APY as of October 2025. Beyond staking, Solana Company plans to pursue additional yield through DeFi lending, liquid staking tokens, covered call programs, and basis trading. The company also runs a two-sided capital management framework: issuing shares accretively when trading at a premium to NAV, and buying back shares when trading at a discount. The company retains a small legacy neurotechnology business — the PoNS device, which treats gait and balance deficits — but this is now a secondary operation. Solana Company was originally founded as Helius Medical Technologies in 2014 and pivoted to its current DAT strategy in September 2025, following a $500M+ PIPE transaction anchored by Pantera Capital.